AMAM Nasdaq· Ambrx Biopharma Inc
FundamentalsNews digest Peer analysis
AMAM Nasdaq· Ambrx Biopharma Inc
Earnings report Q3 2023

AMBRX Biopharma Reports Significant Decline in Revenue for the Latest Quarter

Segments of Revenue

AMBRX Biopharma's revenue for the three months ended September 30, 2023, was only $53,000, representing a substantial decrease of $1.54 million or 96.7% compared to the same period in 2022. The breakdown of revenue segments is as follows:

  • Reimbursements: $53,000
  • License fees: $0
  • Research and development services: $0


Despite the significant decline in revenue, AMBRX Biopharma's management comments that the company's focus remains on research and development agreements. They highlight that the revenue generated from these agreements includes upfront payments for license fees, reimbursements, milestones, and other contingent payments. While the revenue from product sales is yet to be realized, the company's ability to successfully develop, obtain regulatory approval, and commercialize its product candidates remains crucial for future revenue generation.


AMBRX Biopharma faced several challenges in the latest quarter, resulting in a substantial decline in revenue. The company did not generate any revenue from license fees or research and development services during this period. This lack of revenue diversification poses a risk to the company's financial stability and growth potential. Additionally, the inability to predict the amount and timing of future product revenue further adds to the uncertainty surrounding AMBRX Biopharma's financial performance.


AMBRX Biopharma's revenue for the nine months ended September 30, 2023, was $1.2 million, reflecting a significant decrease of $3.31 million or 73.4% compared to the same period in 2022. The company's operating expenses also decreased by 10.6% during this period. Furthermore, AMBRX Biopharma reported a loss from operations of $60.83 million for the nine months ended September 30, 2023, representing a decrease of 6.2% compared to the previous year.


AMBRX Biopharma experienced a substantial decline in revenue for the latest quarter, primarily driven by the absence of revenue from license fees and research and development services. The company's focus on research and development agreements remains a strength, but the lack of revenue diversification and uncertainty surrounding future product revenue pose significant challenges. Despite the decline in revenue, AMBRX Biopharma managed to decrease its operating expenses. The company's financial performance and ability to generate product revenue will heavily rely on successful product development, regulatory approval, and commercialization efforts.

Source documents

Form 10-Q  filed on Nov 13, 2023
3 pages scanned

Reference data

Company financials Q3 revenue 1.5M
Analyst estimates Q3 EPS missed by NaN%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.